Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of nolasiban for in-vitro fertilisation

Next Previous
X
Search
Trial Profile

Phase III study of nolasiban for in-vitro fertilisation

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nolasiban (Primary)
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPLANT 3
  • Sponsors ObsEva

    • Most Recent Events

    • 31 Oct 2019 According to a ObsEva media release, the U.S. Food and Drug Administration (FDA) has allowed the Company to begin enrolling patients in this trial.
    • 19 Jun 2019 According to an ObsEva media release, the Company had an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), addressing a range of issues important to the trial design of nolasiban for increasing the rate of live births in women undergoing single blastocyst transfer (Day 5 SET) following in vitro fertilization (IVF). The company expects to submit the IMPLANT 3 trial protocol with an updated IND in the third quarter of 2019.
    • 19 Jun 2019 According to an ObsEva media release, the Company anticipates beginning this trial in the fourth quarter of this year or early 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top